Amgen: Obesity trials

The registry lists 30 Obesity studies with Amgen as lead sponsor. 8 are open to participants now and 3 have results posted.

Phase 1 15Phase 2 3Phase 3 11No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or OverweightNot yet recruitingNCT07871409Phase 3
• Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNot yet recruitingNCT07866066Phase 3
• Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous DoseNot yet recruitingNCT07832799Phase 1
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)RecruitingNCT07684235Phase 3
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)RecruitingNCT07684144Phase 3
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)RecruitingNCT07575399Phase 3
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityRecruitingNCT07037459Phase 3
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityRecruitingNCT07037433Phase 3
• Single and Multiple Ascending Dose Study of AMG 133 in Participants With ObesityCompletedNCT04478708Phase 1Results posted
• Single and Multiple Ascending Dose Study of AMG 171 in Subjects With ObesityTerminatedNCT04199351Phase 1Results posted
• Multiple Ascending Dose Study of AMG 598 in Adults With ObesityCompletedNCT03757130Phase 1Results posted
• A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityCompletedNCT07717814Phase 1
• Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityActive, not recruitingNCT07523711Phase 1
• A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightActive, not recruitingNCT07441252Phase 2
• A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the BodyCompletedNCT07429045Phase 1
• The Effect of AMG 133 on Gastric EmptyingCompletedNCT07429032Phase 1
• A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsCompletedNCT07313761Phase 1
• A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityCompletedNCT07310563Phase 1
• Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityCompletedNCT07229157Phase 1
• Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsCompletedNCT07226778Phase 1
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyActive, not recruitingNCT07226765Phase 3
• Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyActive, not recruitingNCT07225686Phase 3
• A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityCompletedNCT06976372Phase 1
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightActive, not recruitingNCT06858878Phase 3
• Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightActive, not recruitingNCT06858839Phase 3
• A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight LossCompletedNCT06761703
• A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)Active, not recruitingNCT06660173Phase 2
• A Study to Evaluate AMG 133 in Chinese Participants With Obesity or OverweightCompletedNCT06352892Phase 1
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusCompletedNCT05669599Phase 2
• Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With ObesityCompletedNCT05406115Phase 1